Abbott CEO Silent On $5.8B Alere Deal Amid FCPA Scrutiny
The CEO of Abbott Laboratories on Wednesday would not recommit to a proposed $5.8 billion acquisition of diagnostic testing giant Alere, which recently became the target of a Foreign Corrupt Practices...To view the full article, register now.
Already a subscriber? Click here to view full article